| abstract |
The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof: n n n n n n n n n n wherein:n A is C 1-6 alkyl, C 3-6 cycloalkyl, —CH 2 —R 6 , —CHMe-R 7 , —CMe 2 -R 7 , or optionally substituted aryl; wherein, when A is optionally substituted aryl, said aryl group is optionally substituted with 1 to 3 substituents, which may be the same or different, selected from the group consisting of halogen, C 1-6 alkyl, —CF 3 , C 1-4 alkoxy, C 1 fluoroalkoxy, cyano, NR 8 R 9 , and pyridyl wherein the pyridyl is optionally substituted by one methyl; R 1 is chlorine, fluorine, —CF 3 , cyano or C 1-6 alkyl; R 2 , R 3 and R 5 independently are hydrogen, fluorine, chlorine, —CF 3 , cyano or C 1-6 alkyl, such that at least one of R 2 , R 3 and R 5 is other than hydrogen; R 4 is hydrogen. nn These compounds and salts are thought to be P2X7 receptor antagonists. The invention also provides for the treatment of pain, inflammation, rheumatoid arthritis, osteoarthritis, or a neurodegenerative disease. |